MSR1 and cancer: The current results also suggest the possibility that intralymphatic cancer cells with a low level of ALDH1 expression and CD204(+) macrophages could be useful as a new molecular target, especially as an adjuvant therapy, in patients exhibiting lymphatic permeation.